Forte Biosciences, Inc. (FBRX)
Automate Your Wheel Strategy on FBRX
With Tiblio's Option Bot, you can configure your own wheel strategy including FBRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FBRX
- Rev/Share 0.0032
- Book/Share 8.3968
- PB 1.3904
- Debt/Equity 0.0
- CurrentRatio 11.7357
- ROIC -0.443
- MktCap 145153570.0
- FreeCF/Share -3.291
- PFCF -3.7556
- PE -3.2298
- Debt/Assets 0.0
- DivYield 0
- ROE -0.8538
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | FBRX | Guggenheim | -- | Buy | -- | $75 | Aug. 18, 2025 |
| Initiation | FBRX | TD Cowen | -- | Buy | -- | -- | Jan. 21, 2025 |
News
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
Published: September 15, 2025 by: Business Wire
Sentiment: Neutral
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation “FB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study - Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital” at the Tampere Celiac Disease Symposium 2025 (Tampere, Finland).
Read More
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be.
Read More
About Forte Biosciences, Inc. (FBRX)
- IPO Date 2017-04-13
- Website https://www.fortebiorx.com
- Industry Biotechnology
- CEO Paul A. Wagner
- Employees 14